Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis. (2023)


No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2214-109x(23)00383-2

PubMed Identifier: 37734807

Publication URI: http://europepmc.org/abstract/MED/37734807

Type: Journal Article/Review

Volume: 11

Parent Publication: The Lancet. Global health

Issue: 10

ISSN: 2214-109X